JP2018512873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512873A5 JP2018512873A5 JP2017554902A JP2017554902A JP2018512873A5 JP 2018512873 A5 JP2018512873 A5 JP 2018512873A5 JP 2017554902 A JP2017554902 A JP 2017554902A JP 2017554902 A JP2017554902 A JP 2017554902A JP 2018512873 A5 JP2018512873 A5 JP 2018512873A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- protein
- group
- actriib
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 206010028289 Muscle atrophy Diseases 0.000 claims 7
- 201000000585 muscular atrophy Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 102000037280 Growth Differentiation Factor 2 Human genes 0.000 claims 4
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 claims 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 4
- 208000029578 Muscle disease Diseases 0.000 claims 4
- 108010056852 Myostatin Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108010023082 activin A Proteins 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108010059616 Activins Proteins 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 3
- 239000000488 activin Substances 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 230000020763 muscle atrophy Effects 0.000 claims 3
- 208000001076 sarcopenia Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000037157 Azotemia Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000009852 uremia Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000025494 Aortic disease Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000001826 Marfan syndrome Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000025584 Pericardial disease Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 238000009167 androgen deprivation therapy Methods 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 208000022806 beta-thalassemia major Diseases 0.000 claims 1
- 208000037877 cardiac atrophy Diseases 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 238000005265 energy consumption Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000005486 microgravity Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 230000033667 organ regeneration Effects 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000017423 tissue regeneration Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021139606A JP7320571B2 (ja) | 2015-04-22 | 2021-08-30 | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150994P | 2015-04-22 | 2015-04-22 | |
| US62/150,994 | 2015-04-22 | ||
| US201562262356P | 2015-12-02 | 2015-12-02 | |
| US62/262,356 | 2015-12-02 | ||
| PCT/US2016/027046 WO2016171948A1 (en) | 2015-04-22 | 2016-04-12 | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021139606A Division JP7320571B2 (ja) | 2015-04-22 | 2021-08-30 | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512873A JP2018512873A (ja) | 2018-05-24 |
| JP2018512873A5 true JP2018512873A5 (cg-RX-API-DMAC7.html) | 2019-11-14 |
| JP6959487B2 JP6959487B2 (ja) | 2021-11-02 |
Family
ID=57144520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554902A Active JP6959487B2 (ja) | 2015-04-22 | 2016-04-12 | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
| JP2021139606A Active JP7320571B2 (ja) | 2015-04-22 | 2021-08-30 | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021139606A Active JP7320571B2 (ja) | 2015-04-22 | 2021-08-30 | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
Country Status (24)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
| JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 |
| JP7055636B2 (ja) | 2015-04-06 | 2022-04-18 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| US10722558B2 (en) | 2016-07-15 | 2020-07-28 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| KR102761094B1 (ko) | 2016-10-05 | 2025-02-03 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| JP7219705B2 (ja) | 2016-10-05 | 2023-02-08 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| US11013785B2 (en) | 2016-11-10 | 2021-05-25 | Keros Therapeutics, Inc. | Activin receptor type IIA variants and methods of use thereof |
| EP3600415B1 (en) * | 2017-03-24 | 2025-09-17 | Novartis AG | Antibody against activin receptor type ii receptor for use in treating heart failure |
| KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN120535607A (zh) * | 2018-01-12 | 2025-08-26 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| AU2019266314B2 (en) | 2018-05-09 | 2025-05-15 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CA3142149A1 (en) * | 2019-05-30 | 2020-12-03 | Acceleron Pharma, Inc. | Actrii-binding proteins and uses thereof |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| KR20220148189A (ko) * | 2020-02-03 | 2022-11-04 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| US20230129812A1 (en) * | 2020-02-03 | 2023-04-27 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| EP4121078A4 (en) * | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| BR112022020628A2 (pt) * | 2020-04-13 | 2022-11-29 | Celgene Corp | Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| IL300362A (en) * | 2020-08-20 | 2023-04-01 | Regeneron Pharma | Methods to prevent and treat poor cardiac function and covid-19 with activin A antagonists |
| US20240181007A1 (en) * | 2021-01-08 | 2024-06-06 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| CA3243129A1 (en) | 2022-01-28 | 2023-08-03 | 35Pharma Inc. | Type IIB Activin Receptor Variants and Their Uses |
| EP4653010A1 (en) * | 2024-05-14 | 2025-11-26 | 35Pharma Inc. | Activin receptor type iib traps for use in improving body composition |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| DE60027135T2 (de) | 1999-01-21 | 2007-01-11 | Metamorphix, Inc. | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| CN1330664C (zh) * | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | 用于含杂合同种型抗体部分的蛋白质的表达技术 |
| AU2012204098B2 (en) | 2001-04-24 | 2014-05-15 | The Johns Hopkins University | Use of follistatin to increase muscle mass |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
| EP1682584B1 (en) * | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| AU2015200950B2 (en) | 2004-07-23 | 2017-04-27 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| EP1778275A2 (en) | 2004-08-12 | 2007-05-02 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| EP2468290B1 (en) | 2006-12-18 | 2015-04-01 | Acceleron Pharma, Inc. | Activin-ActRII Antagonists for use in treating anemia |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| WO2013106175A1 (en) * | 2011-12-19 | 2013-07-18 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| US7947646B2 (en) * | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| WO2009038745A1 (en) * | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| JP5773868B2 (ja) | 2008-06-26 | 2015-09-02 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用 |
| US20100015144A1 (en) | 2008-06-26 | 2010-01-21 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| US8058229B2 (en) | 2008-08-14 | 2011-11-15 | Acceleron Pharma Inc. | Method of increasing red blood cell levels or treating anemia in a patient |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MY159483A (en) | 2008-11-26 | 2017-01-13 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| HUE035240T2 (hu) | 2009-04-27 | 2018-05-02 | Novartis Ag | Készítmények és eljárások az izomerõ növelésére |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| CN113171442B (zh) | 2009-08-13 | 2024-11-15 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| MX340451B (es) | 2009-09-09 | 2016-07-08 | Acceleron Pharma Inc | Antagonistas de actriib y dosificacion y usos de los mismos. |
| JP5836961B2 (ja) | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ， インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US20110268736A1 (en) | 2010-04-30 | 2011-11-03 | Children's Medical Center Corporation | Method for treating congenital myopathy |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| DK3520805T3 (da) | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| WO2014066486A2 (en) | 2012-10-24 | 2014-05-01 | Celgene Corporation | Biomarker for use in treating anemia |
| AU2013337677B2 (en) | 2012-11-02 | 2018-06-28 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| US20140220033A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| CA2931615A1 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| KR20160127148A (ko) | 2014-03-21 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| EP3131931B1 (en) | 2014-04-18 | 2020-10-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
| CA2952231A1 (en) | 2014-06-13 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Formulated receptor polypeptides and related methods |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| CN107533040B (zh) | 2014-12-03 | 2022-03-29 | 细胞基因公司 | 激活素-actrii拮抗剂及用于治疗贫血症的用途 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| JP7055636B2 (ja) | 2015-04-06 | 2022-04-18 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| CA2996996A1 (en) | 2015-08-31 | 2017-03-09 | National Research Council Of Canada | Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| WO2017091706A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| KR20180128405A (ko) | 2016-02-22 | 2018-12-03 | 악셀레론 파마 인코포레이티드 | 면역 활성 증가에 사용하기 위한 ActRII 길항제 |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| KR102761094B1 (ko) | 2016-10-05 | 2025-02-03 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
-
2016
- 2016-04-12 SM SM20210294T patent/SMT202100294T1/it unknown
- 2016-04-12 LT LTEP16783603.0T patent/LT3286206T/lt unknown
- 2016-04-12 SI SI201631191T patent/SI3286206T1/sl unknown
- 2016-04-12 SG SG11201708351XA patent/SG11201708351XA/en unknown
- 2016-04-12 ES ES16783603T patent/ES2856001T3/es active Active
- 2016-04-12 RU RU2017138537A patent/RU2733492C2/ru active
- 2016-04-12 EP EP21156657.5A patent/EP3878857A1/en not_active Withdrawn
- 2016-04-12 HR HRP20210725TT patent/HRP20210725T1/hr unknown
- 2016-04-12 JP JP2017554902A patent/JP6959487B2/ja active Active
- 2016-04-12 SG SG10201913747PA patent/SG10201913747PA/en unknown
- 2016-04-12 US US15/568,232 patent/US10913782B2/en active Active
- 2016-04-12 KR KR1020177033601A patent/KR102777477B1/ko active Active
- 2016-04-12 PT PT167836030T patent/PT3286206T/pt unknown
- 2016-04-12 CN CN201680036599.1A patent/CN107683287B/zh active Active
- 2016-04-12 PL PL16783603T patent/PL3286206T3/pl unknown
- 2016-04-12 WO PCT/US2016/027046 patent/WO2016171948A1/en not_active Ceased
- 2016-04-12 RS RS20210563A patent/RS61881B1/sr unknown
- 2016-04-12 DK DK16783603.0T patent/DK3286206T3/da active
- 2016-04-12 AU AU2016251640A patent/AU2016251640B2/en active Active
- 2016-04-12 MX MX2017013520A patent/MX2017013520A/es unknown
- 2016-04-12 EP EP16783603.0A patent/EP3286206B1/en active Active
- 2016-04-12 CA CA2983440A patent/CA2983440C/en active Active
- 2016-04-12 HU HUE16783603A patent/HUE054232T2/hu unknown
-
2017
- 2017-10-16 IL IL255070A patent/IL255070B/en unknown
- 2017-11-17 ZA ZA2017/07821A patent/ZA201707821B/en unknown
-
2020
- 2020-06-08 US US16/895,670 patent/US11292826B2/en active Active
- 2020-10-07 AU AU2020250216A patent/AU2020250216B2/en active Active
- 2020-11-16 ZA ZA2020/07118A patent/ZA202007118B/en unknown
-
2021
- 2021-05-14 CY CY20211100411T patent/CY1124124T1/el unknown
- 2021-08-30 JP JP2021139606A patent/JP7320571B2/ja active Active
-
2022
- 2022-02-28 US US17/682,277 patent/US11932677B2/en active Active
-
2024
- 2024-02-07 US US18/435,934 patent/US20240262883A1/en not_active Abandoned